Literature DB >> 23040595

Comparison of Three-year outcomes after primary percutaneous coronary intervention in patients with left ventricular ejection fraction <40% versus ≥ 40% (from the HORIZONS-AMI trial).

Benoit Daneault1, Philippe Généreux, Ajay J Kirtane, Bernhard Witzenbichler, Giulio Guagliumi, Jean-Michel Paradis, Martin P Fahy, Roxana Mehran, Gregg W Stone.   

Abstract

Left ventricular (LV) dysfunction and multivessel disease (MVD) have been associated with greater mortality after ST-segment elevation myocardial infarction. The aim of this study was to evaluate the impact of LV dysfunction and MVD in patients with ST-segment elevation myocardial infarctions treated with primary percutaneous coronary intervention (PCI). Patients from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial treated with primary PCI in whom baseline LV function was assessed using left ventriculography were included in this study. Early and late (3-year) outcomes were examined in groups of patients with reduced (<40%) and preserved (≥ 40%) LV ejection fractions (LVEFs), further stratified by the presence of MVD. A total of 2,430 patients were included. Patients with reduced LVEFs were older; were more likely to be women; were more likely to have histories of myocardial infarction, PCI, and heart failure; and were more likely to present in heart failure. Patients with reduced LVEFs had greater 30-day (8.9% vs 0.9%, hazard ratio 9.81, 95% confidence interval 5.23 to 18.42, p <0.0001) and 3-year (17.1% vs 3.7%, hazard ratio 5.03, 95% confidence interval 3.37 to 7.50, p <0.0001) mortality. Among patients with LVEFs <30% (n = 45), 30% to 40% (n = 157), 40% to 50% (n = 373), 50% to 60% (n = 659), and ≥ 60% (n = 1,196), 3-year mortality was 29.4%, 13.5%, 6.4%, 3.8%, and 2.9%, respectively (p for trend <0.0001). MVD was associated with greater mortality in patients with preserved but not reduced LVEFs. By multivariate analysis, LV dysfunction was the strongest predictor of 30-day and 3-year mortality. In conclusion, the presence of LV dysfunction as assessed on baseline left ventriculography in patients who undergo primary PCI in the contemporary era is a powerful predictor of early and late mortality, regardless of the extent of coronary artery disease.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23040595     DOI: 10.1016/j.amjcard.2012.08.040

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

1.  Combined assessment of left ventricular end-diastolic pressure and ejection fraction by left ventriculography predicts long-term outcomes of patients with ST-segment elevation myocardial infarction.

Authors:  Daiga Saito; Rine Nakanishi; Ippei Watanabe; Takayuki Yabe; Ryo Okubo; Hideo Amano; Mikihito Toda; Takanori Ikeda
Journal:  Heart Vessels       Date:  2017-11-15       Impact factor: 2.037

2.  Natural IgM Blockade Limits Infarct Expansion and Left Ventricular Dysfunction in a Swine Myocardial Infarct Model.

Authors:  Smita Sihag; Michael S Haas; Karen M Kim; J Luis Guerrero; Jonathan Beaudoin; Elisabeth M Alicot; Franziska Schuerpf; James D Gottschall; Robyn J Puro; Joren C Madsen; David H Sachs; Walter Newman; Michael C Carroll; James S Allan
Journal:  Circ Cardiovasc Interv       Date:  2016-01       Impact factor: 6.546

3.  In-hospital measurement of left ventricular ejection fraction and one-year outcomes in acute coronary syndromes: results from the IMMEDIATE Trial.

Authors:  Jayanta T Mukherjee; Joni R Beshansky; Robin Ruthazer; Hadeel Alkofide; Madhab Ray; David Kent; Warren J Manning; Gordon S Huggins; Harry P Selker
Journal:  Cardiovasc Ultrasound       Date:  2016-08-03       Impact factor: 2.062

4.  Relationship between lncRNA-Ang362 and prognosis of patients with coronary heart disease after percutaneous coronary intervention.

Authors:  Hui Wang; Huichao Gong; Yingwu Liu; Limin Feng
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

5.  Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials.

Authors:  Yingxu Ma; Fan Bai; Fen Qin; Jiayi Li; Na Liu; Dongping Li; Tengfang Li; Hui Xie; Da Liu; Shenghua Zhou; Qiming Liu
Journal:  BMC Pharmacol Toxicol       Date:  2019-04-25       Impact factor: 2.483

6.  Comparison of the TIMI, GRACE, PAMI and CADILLAC risk scores for prediction of long-term cardiovascular outcomes in Taiwanese diabetic patients with ST-segment elevation myocardial infarction: From the registry of the Taiwan Society of Cardiology.

Authors:  Yung-Ta Kao; Yi-Chen Hsieh; Chien-Yi Hsu; Chun-Yao Huang; Ming-Hsiung Hsieh; Yung-Kuo Lin; Jong-Shiuan Yeh
Journal:  PLoS One       Date:  2020-02-13       Impact factor: 3.240

7.  Enhanced Inflammation is a Marker for Risk of Post-Infarct Ventricular Dysfunction and Heart Failure.

Authors:  Iwona Świątkiewicz; Przemysław Magielski; Jacek Kubica; Adena Zadourian; Anthony N DeMaria; Pam R Taub
Journal:  Int J Mol Sci       Date:  2020-01-26       Impact factor: 5.923

8.  Association of genetic variants in lncRNA GAS5/miR-21/mTOR axis with risk and prognosis of coronary artery disease among a Chinese population.

Authors:  Hu Li; Yingxue Liu; Jinyan Huang; Yu Liu; Yufeng Zhu
Journal:  J Clin Lab Anal       Date:  2020-06-17       Impact factor: 2.352

9.  Relationship between long non-coding RNA and prognosis of patients with coronary heart disease after percutaneous coronary intervention: A protocol for systematic review and meta-analysis.

Authors:  Fei Wang; Xiaoqing Cai; Piqi Jiao; Yan Liu; Bin Yuan; Peng Zhang; Hongbin Liu; Ling Ma
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

10.  The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: the BAMI trial.

Authors:  Anthony Mathur; Francisco Fernández-Avilés; Jozef Bartunek; Ann Belmans; Filippo Crea; Sheik Dowlut; Manuel Galiñanes; Marie-Claire Good; Juha Hartikainen; Christine Hauskeller; Stefan Janssens; Petr Kala; Jens Kastrup; John Martin; Philippe Menasché; Ricardo Sanz-Ruiz; Seppo Ylä-Herttuala; Andreas Zeiher
Journal:  Eur Heart J       Date:  2020-10-07       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.